A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD
Background: With the increasing recognition of adult attention-deficit/hyperactivity disorder (ADHD) there is an emerging need to investigate medication in this population. Methods: In this waiting list-controlled trial, 64 ADHD-patients (mean age 35.8±8.7 years) were randomly assigned to a daily do...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2012
|
| In: |
Pharmacopsychiatry
Year: 2011, Volume: 45, Issue: 03, Pages: 100-107 |
| ISSN: | 1439-0795 |
| DOI: | 10.1055/s-0031-1291319 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1055/s-0031-1291319 Verlag, Volltext: http://www.thieme-connect.de.ezproxy.medma.uni-heidelberg.de/DOI/DOI?10.1055/s-0031-1291319 
|
| Author Notes: | E. Sobanski, D. Sabljic, B. Alm, C. Baehr, R.W. Dittmann, G. Skopp, P. Strohbeck-Kuehner |
| Summary: | Background: With the increasing recognition of adult attention-deficit/hyperactivity disorder (ADHD) there is an emerging need to investigate medication in this population. Methods: In this waiting list-controlled trial, 64 ADHD-patients (mean age 35.8±8.7 years) were randomly assigned to a daily dosage of up to 80 mg atomoxetine (Atx) or waiting list for 12-weeks. Primary outcome was the change of the observer-rated DSM-IV total ADHD score on the Conners’ Adult ADHD Rating Scales (CAARS-O:L DSM-IV total ADHD score) from baseline to endpoint. Other efficacy measures included self-rated CAARS-S:L DSM-IV total ADHD score, CAARS-O/S:L problems with self-concept and emotional lability score, Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation Score, and General Activities Score on the Quality of Life Enjoyment and Satisfaction Questionnaire. Efficacy measures were analysed in the per-protocol population. Results: Mean change in CAARS:O-L DSM-IV total ADHD score was - 13.1±7.7 in the Atx vs. - 0.4±4.8 in the control group (p<0.005). Treatment response (≥30% reduction) was 60.1% in the Atx vs. 0% in the waiting list group. The other efficacy measures also showed significant improvements. The overall incidence of adverse events (AEs) was 70.4% in the Atx group, the most frequent included fatigue, irritability, nausea and decreased appetite. In Atx-treated patients 18.5% discontinued early due to AEs. Discussion: Our results suggest that Atx is an effective treatment in adult ADHD. It reduces ADHD core and associated emotional symptoms and increases self-esteem and quality of life. AEs were consistent with those reported in other studies in adult ADHD. |
|---|---|
| Item Description: | Published online ahead of print: 15 December 2011 Gesehen am 07.06.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1439-0795 |
| DOI: | 10.1055/s-0031-1291319 |